Design: Multicentre, open-label, randomised controlled trial with an active digital comparator
Population: 605 adults with stage I–III breast cancer starting systemic therapy (487 analysed)
Primary outcome: PROMIS-29 quality-of-life domains at end of treatment
Effect: Fatigue −3.90 (−5.77 to −2.03); anxiety −2.10 (−3.65 to −0.55); all below the 5-point MID

ENABLE, a randomised trial at two German university hospitals published in the Journal of Medical Internet Research on 28 October, enrolled 605 patients starting systemic therapy for stage I to III breast cancer. Both groups had a supportive app and scheduled quality-of-life questionnaires. One group also completed a weekly wellbeing score; a low score or a sharp drop triggered a symptom check and an alert to the care team.

By the end of treatment, the triage group had less fatigue, less anxiety and better social participation. All differences were smaller than the threshold usually considered clinically important. Three-quarters of monitored patients triggered at least one alert. No harms were found.

The benefit of electronic symptom monitoring seen in metastatic disease was smaller here, partly because the comparison group already had an active app. The authors frame triage as a workflow tool that works only when someone acts on the alerts.

Consider symptom-triggered triage only where a named team will respond to alerts.
Expect most patients to trigger at least one alert during treatment; plan the workload.
Do not expect large quality-of-life gains in early breast cancer from monitoring alone.
Fatigue was the domain most improved.

Why it matters

It tempers expectations set by monitoring trials in advanced cancer.

The statistics, in plain English

The fatigue difference of −3.9 T-score points (95% CI −5.8 to −2.0) is statistically clear but below the 5-point minimal important difference, so most patients would not notice it.